Adtralza
(Tralokinumab)Phase 3Monoclonal antibody
LEO PharmaTralokinumab is used to treat moderate to severe atopic dermatitis (eczema), a skin condition that causes itching, redness, and inflammation. It works by blocking a specific protein in the body that triggers the inflammatory response in the skin.[1] Adtralza is currently being investigated across 4 indications[3], with its most advanced program in Phase 3.[1]
Adtralza is one of 100 monoclonal antibody programs targeting Atopic Eczema. It is currently in Phase 3.
4
Indications
31
Total Trials
7
Active Trials
99
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
116 competitors in Atopic Dermatitis
#DrugCompanyPhaseTrials
1Fludara
SanofiPhase 3
Cytosar
TevaPhase 3
Adtralza
LEO PharmaPhase 3
Amlitelimab
SanofiPhase 3
Certolizumab
Johnson & JohnsonPhase 3
DUPIXENT
RegeneronPhase 3
ICP-332
BBeijing InnoCare Pharma Tech Co., Ltd.
Phase 3
VC005
JJiangsu vcare pharmaceutical technology co., LTD
Phase 3
LNK01001
LLynk Pharmaceuticals Co., Ltd
Phase 3
MG-K10
SShanghai Mabgeek Biotech.Co.Ltd
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atopic Dermatitis17 trials
Show 14 more trials
Asthma6 trials
Show 3 more trials
5 more indications
Ulcerative Colitis1 trial
Pregnancy1 trial
Idiopathic Pulmonary Fibrosis1 trial
Liver1 trial
Unspecified1 trial
Tralokinumab for Dupilumab Failures
Active, not recruiting·PPsoriasis Treatment Center of Central New Jersey·Phase 4·NCT06773455·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tralokinumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- IL-13 Inhibitor[2]
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company